ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2014
Pathogen inactivation technologies for cellular blood components: an update.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex.Transfusion · 2026Article
- Article
- Platelet Transfusion for Patients with Cancer: An Update.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
- Impact of 450 nm blue light on platelet multiomics and bacterial inactivation.Lasers in medical science · 2025Article
- Microbial reduction of prebagged human plasma using 405 nm light and its effects on coagulation factors.AMB Express · 2024Article
- The Preclinical Validation of 405 nm Light Parasiticidal Efficacy onMicroorganisms · 2024Article
- Cationic Porphyrins as Antimicrobial and Antiviral Agents in Photodynamic Therapy.Current issues in molecular biology · 2023Review
- Analysis of Transfusion-Transmitted Bacterial Infections according to German Hemovigilance Data (2011-2020).Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Article
- Pathogen inactivation treatment of triple-dose apheresis platelets with amotosalen and ultraviolet a light.Transfusion medicine (Oxford, England) · 2022Article
- Hemoglobin Oxidation Reactions in Stored Blood.Antioxidants (Basel, Switzerland) · 2022Article
- In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.Pathogens (Basel, Switzerland) · 2022Article
- Visual Assessment of Blood Plasma versus Optical Transmittance and Refractive Index Measurements for Quantifying Lipemia.Diagnostics (Basel, Switzerland) · 2022Article
- A minimally manipulated preservation and virus inactivation method for amnion/chorion.Frontiers in bioengineering and biotechnology · 2022Article
- Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production.International journal of molecular sciences · 2021Review
- 10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil.Vox sanguinis · 2021Article
- Novel approaches for COVID-19 diagnosis and treatment: a nonsystematic review.Turkish journal of biology = Turk biyoloji dergisi · 2021Review
- A Blood Bank Standardized Production of Human Platelet Lysate for Mesenchymal Stromal Cell Expansion: Proteomic Characterization and Biological Effects.Frontiers in cell and developmental biology · 2021Article
- Infectious complications in neonatal transfusion: Narrative review and personal contribution.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020Review
- Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.Transfusion · 2020Article
- The Effects of Gamma Irradiation on Chemical Biomarker Recovery from Mixed Chemical/Biological Threat Exposure Specimens.The journal of applied laboratory medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays patients receiving blood components are exposed to much less transfusion-transmitted infectious diseases than three decades before when among others HIV was identified as causative agent for the acquired immunodeficiency syndrome and the transmission by blood or coagulation factors became evident. Since that time the implementation of measures for risk prevention and safety precaution was socially and politically accepted. Currently emerging pathogens like arboviruses and the well-known bacterial contamination of platelet concentrates still remain major concerns of blood safety with important clinical consequences, but very rarely with fatal outcome for the blood recipient. In contrast to the well-established pathogen inactivation strategies for fresh frozen plasma using the solvent-detergent procedure or methylene blue and visible light, the bench-to-bedside translation of novel pathogen inactivation technologies for cell-containing blood components such as platelets and red blood cells are still underway. This review summarizes the pharmacological/toxicological assessment and the inactivation efficacy against viruses, bacteria, and protozoa of each of the currently available pathogen inactivation technologies and highlights the impact of the results obtained from several randomized clinical trials and hemovigilance data. Until now in some European countries pathogen inactivation technologies are in in routine use for single-donor plasma and platelets. The invention and adaption of pathogen inactivation technologies for red blood cell units and whole blood donations suggest the universal applicability of these technologies and foster a paradigm shift in the manufacturing of safe blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.